Clinical significance of selective serotonin reuptake inhibitor (SSRI) in the treatment of depression

Folia Pharmacologica Japonica

Volumn 116, Issue 2, 2000, Pages 79-84

  Semba, J ^a  

^a OPEN UNIVERSITY OF JAPAN   (Japan)

Author keywords

Antidepressant; Anxiety disorder; Depression; Selective serotonin reuptake inhibitor

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

ANXIETY NEUROSIS; CHRONIC DISEASE; DEPRESSION; DISEASE SEVERITY; HUMAN; MAINTENANCE THERAPY; OBSESSION; PANIC; PATHOPHYSIOLOGY; PSYCHOTHERAPY; REVIEW; SEROTONINERGIC SYSTEM; SOCIAL PHOBIA;

EID: 0033835962     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.116.79     Document Type: Review

References (38)

1. SSRIS versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability
2. Selective serotonin reuptake inhibitors. Relevance of difference in their pharmacological and clinical profiles
3. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis
4. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta-analysis
5. Factors associated with 1-year outcome of major depression in the community
6. Relapse and recurrence of depression: A practical approach for prevention
7. Continuation drug therapy for major depressive episodes: How long should it be maintained?
8. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence
9. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression
10. Sertraline in the prevention of depression
11. Fluvoxamine prevents recurrence of depression: Results of a long-term, double-blind, placebo-controlled study
12. Three-year outcomes for maintenance therapies in recurrent depression
13. Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression
14. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia
15. Epidemiology of depression and anxiety disorders
16. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar depressive disorders
17. Subclinical symptoms in mood disorders: Pathophysiological and therapeutic implications
18. Biogenic amines and depression: Biochemical and pharmacological separation of two types of depression
19. Noradrenergic and serotoninergic depression?
20. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression
21. A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression
22. Anti-depressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: A review
23. Reboxetine: A double-blind comparison with fluoxetine in major depressive disorder
24. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale
25. Noradrenaline-selective versus serotonin-selective antidepressant therapy: Differential effects on social functioning
26. Research report: Predictors of response to amine-specific anti-depressants
27. Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder
28. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder
29. Current concepts in the treatment of panic disorder
30. Comorbidity of DSM-III-R major depressive disorder in the general population: Results from the US National Comorbidity Survey
31. Cross-national epidemiology of major depression and bipolar disorder
32. Differential effects of alprazolam and imipramine in generalized anxiety disorder: Somatic versus psychic symptoms
33. Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious out-patients
34. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia
35. Interest of a loading dose of milnacipran in endogenous depressive inpatients Comparison with the standard regimen and with fluvoxamine